Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Immunology

Background:

• Phosphoinositide 3-kinase gamma (PI3Kγ) is a key mediator in inflammatory responses.
• Developing isoform-selective PI3Kγ inhibitors is crucial for targeted anti-inflammatory therapies.
• Existing inhibitors may lack selectivity or suitable pharmacokinetic profiles.

Purpose of the Study:

• To discover and optimize a novel chemotype of PI3Kγ inhibitors.
• To identify compounds with high potency, selectivity, and favorable ADME properties.
• To evaluate the in vivo efficacy of lead compounds in an inflammatory model.

Main Methods:

• High-throughput screening (HTS) to identify initial hits.
• Structure-activity relationship (SAR) studies for chemical optimization.
• In vitro assays for potency and selectivity profiling.
• In vivo pharmacokinetic and pharmacodynamic studies in animal models.

Main Results:

• Discovery of a new chemotype of PI3Kγ inhibitors.
• Optimization led to compound 15, a potent and highly selective PI3Kγ inhibitor.
• Compound 15 demonstrated suitable ADME properties for oral administration.
• In vivo studies showed dose-dependent inhibition of LPS-induced airway neutrophilia in rats.

Conclusions:

• Successful discovery and optimization of a novel PI3Kγ inhibitor chemotype.
• Compound 15 represents a promising candidate for oral anti-inflammatory therapy.
• Further development of compound 15 warrants investigation for treating inflammatory conditions.